Effect of gilteritinib on immune recovery after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how gilteritinib, a drug used to prevent leukemia from coming back, affects your immune system after a stem cell transplant. It may help doctors understand if this treatment is safe and effective for people like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had a stem cell transplant for acute myeloid leukemia (AML).
- Your doctor plans to give you gilteritinib after the transplant to prevent relapse.
- Your transplant came from a related or unrelated donor, even if partially matched.
- You are not pregnant, not under legal guardianship, and not in prison.
- You have not been treated for a solid tumor in the last 2 years.
- You do not have HIV, active hepatitis B or C, or an allergy to gilteritinib.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two maintenance drugs (gilteritini and sorafenib) for people with FLT3-ITD positive AML after a stem cell transplant. It compares which drug better prevents relapse using a sensitive test for minimal residual disease (MRD).
This trial compares two drugs, ATLG and ATG, to see which one helps rebuild the immune system better after a stem cell transplant for blood cancer. It aims to improve recovery and reduce complications.
This trial tests if adding the targeted drug gilteritinib to standard chemotherapy improves outcomes for adults with a specific type of AML (FLT3-ITD+). It's for newly diagnosed patients who can tolerate intensive treatment.
This study tests a combination of two targeted drugs, gilteritinib and momelotinib, for people whose acute myeloid leukemia (AML) has returned or has not responded to standard treatment. The drugs aim to block signals that help leukemia cells grow, potentially offering a new option for those with a FLT3 mutation.
This trial tests a new combination of drugs (gilteritinib plus a chemo regimen called FLAI) as the first treatment for adults with a specific type of acute myeloid leukemia (AML) that has a FLT3 mutation. The goal is to see if this combination helps destroy leukemia cells better and with acceptable side effects.
This trial tests an oral drug called gilteritinib for people with advanced ALK-positive non-small cell lung cancer that has progressed after prior ALK inhibitor treatment. It aims to see if gilteritinib can help when other treatments have stopped working.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.